Janus kinase inhibitors in giant cell arteritis: unmet needs and new challenges

Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, GR-41223 Larissa, Greece

Reumatologia 2026;64(1):1-3

DOI: https://doi.org/10.5114/reum/218349

Artykuł (PDF)

Referencje (13)

DZIEDZINY

REFERENCJE (13)

Alba MA, Kermani TA, Unizony S, et al. Relapses in giant cell arteritis: Updated review for clinical practice. Autoimmun Rev 2024; 23: 103580, DOI: 10.1016/j.autrev.2024.103580.

CrossRef

Google Scholar

Pardali EC, Klonizakis M, Goulis DG, et al. Sarcopenia in Rheumatic Diseases: A Hidden Issue of Concern. Diseases 2025; 13: 134, DOI: 10.3390/diseases13050134.

CrossRef

Google Scholar

Alba MA, García-Martínez A, Prieto-González S, et al. Relapses in Patients With Giant Cell Arteritis. Medicine (Baltimore) 2014; 93: 194–201, DOI: 10.1097/MD.0000000000000033.

CrossRef

Google Scholar

Spiera R, Unizony SH, Bao M, et al. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Semin Arthritis Rheum 2021; 51: 469–476, DOI: 10.1016/j.semarthrit.2021.03.006.

CrossRef

Google Scholar

Matza MA, Dagincourt N, Mohan SV, et al. Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis. RMD Open 2023; 9: e002923, DOI: 10.1136/rmdopen-2022-002923.

CrossRef

Google Scholar

Vitiello G, Orsi Battaglini C, Carli G, et al. Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study. Angiology 2018; 69: 763–769, DOI: 10.1177/0003319717753223.

CrossRef

Google Scholar

Rempenault C, Lukas C, Combe B, et al. Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology 2022; 61: 953–962, DOI: 10.1093/rheumatology/keab438.

CrossRef

Google Scholar

Corbera-Bellalta M, Planas-Rigol E, Lozano E, et al. Blocking interferon g reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. Ann Rheum Dis 2016; 75: 1177–1186, DOI: 10.1136/annrheumdis-2015-208371.

CrossRef

Google Scholar

Hur B, Koster MJ, Jang JS, et al. Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Noninflammatory Aortic Aneurysms. Arthritis Rheumatol 2022; 74: 1376–1386, DOI: 10.1002/art.42138.

CrossRef

Google Scholar

10.

Blockmans D, Penn SK, Setty AR, et al. A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. N Engl J Med 2025; 392: 2013–2024, DOI: 10.1056/NEJMoa2413449.

CrossRef

Google Scholar

11.

Sreih AG, Alibaz-Oner F, Kermani TA, et al. Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. J Rheumatol 2017; 44: 1933–1937, DOI: 10.3899/jrheum.161467.

CrossRef

Google Scholar

12.

Sanchez-Alvarez C, Bond M, Soowamber M, et al. Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task forc. RMD Open 2023; 9: e003233, DOI: 10.1136/rmdopen-2023-003233.

CrossRef

Google Scholar

13.

Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022; 386: 316–326, DOI: 10.1056/NEJMoa2109927.

CrossRef

Google Scholar

Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Wyślij swój artykuł

Archiwum

Dla autorów

Udostępnij

Wyślij mailem

Indeksy

Indeks słów kluczowych

Indeks dziedzin

Indeks autorów

eISSN:	2084-9834
ISSN:	0034-6233